Coeptis Therapeutics Holdings Inc
Change company Symbol lookup
Select an option...
COEP Coeptis Therapeutics Holdings Inc
SOFI SoFi Technologies Inc
MBOT Microbot Medical Inc
OLP One Liberty Properties Inc
GNT-A Gamco Natural Resources Gold & Income Trust
AGRI AgriFORCE Growing Systems Ltd
LEN Lennar Corp
PEPL PepperLime Health Acquisition Corp
LOCL Local Bounti Corp
STVN Stevanato Group SpA
Go

Company profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing cell therapy platforms for cancer. The Company's product portfolio and rights are highlighted by a universal, multi-antigen chimeric antigen receptor (CAR)-T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Its CAR T therapies are revolutionizing the treatment of many blood cancers, including B cell leukemias and lymphomas by targeting specific proteins found in these cancers.

Closing Price
$1.95
Day's Change
-0.13 (-6.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.10
Day's Low
1.85
Volume
(Light)
Volume:
41,886

10-day average volume:
104,189
41,886

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing cell therapy platforms for cancer. The Company's product portfolio and rights are highlighted by a universal, multi-antigen chimeric antigen receptor (CAR)-T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Its CAR T therapies are revolutionizing the treatment of many blood cancers, including B cell leukemias and lymphomas by targeting specific proteins found in these cancers.

Valuation Ratios

Price/Earnings (TTM)
3.13x
Price/Sales (TTM)
--
Price/Book (MRQ)
0.63x
Price/Cash Flow (TTM)
1.68x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
18.4K
Previous Month
354.0K
Percent of Float
0.14%
Days to Cover
0.1786 Days

Share Information

COEP is in a share class of common stock
Float
5.1M
Shares Outstanding
5.1M
Institutions Holding Shares
19
54.11%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.